ABSTRACT

Objective:

This study aims to know if patients implanted with the OPTIFLEX Natural Yellow Hydrophilic Aspheric IOL (Moss Vision Inc. Ltd, London, UK) achieved the desired refractive outcome, with reduced reliance on spectacle correction and no significant decline in contrast or inducement/change in spherical aberrations.

Methods:

This study is a single-center retrospective study in patients with cataract. Medical records of patients who were followed up for 6 months were reviewed. Data on distance, intermediate and near visual acuity, refractive error (sphere, cylinder, and manifest spherical equivalent [MSE]), contrast sensitivity, and adverse events were collected and analyzed.

Results:

A total of 48 eyes of 48 patients, with mean age of 66.84±9.72 years (range, 43–88 years) and equal distribution of both genders, were included in the present study. Mean preoperative uncorrected distance visual acuity (UDVA) was 0.81±0.30 LogMAR, and mean UDVA was improved to 0.17±0.15 LogMAR at 6 months follow-up (p<0.001). Mean corrected distance visual acuity (CDVA) was improved to 0.06±0.12 LogMAR at 6 months follow-up (p<0.001). Mean uncorrected intermediate visual acuity (UIVA) and mean uncorrected near visual acuity (UNVA) at 6 months follow-up were 0.30±0.15 LogMAR and 0.31±0.16 LogMAR, respectively. There was statistically no significant change from the preoperative values (p>0.05) in mean refractive spherical equivalent at follow-up visits. An adverse event of diabetic retinopathy, which was nonserious, mild in nature, and unrelated to the study device and index procedure, was reported in one patient.

Conclusion:

The OPTIFLEX Natural Yellow Hydrophilic Aspheric IOL improved visual acuity outcomes in patients who underwent cataract surgery, without any complications, while preserving visual quality.